Therapeutic Potential of Stem Cells Strategy for Cardiovascular Diseases

Stem Cells International

Volumn 2016, Issue , 2016, Pages

  Lee, Chang Youn ^a   Kim, Ran ^b   Ham, Onju ^c   Lee, Jihyun ^b   Kim, Pilseog ^b   Lee, Seokyeon ^b   Oh, Sekyung ^d   Lee, Hojin ^e   Lee, Minyoung ^f   Kim, Jongmin ^g   Chang, Woochul ^b  

^a Yonsei University   (South Korea)

^b Pusan National University   (South Korea)

^c Catholic Kwandong University   (South Korea)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Kyungpook National University   (South Korea)

^g Sookmyung Women's University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA;

ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELL; ADULT STEM CELL THERAPY; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CARDIAC MUSCLE CELL; CARDIAC STEM CELL; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL REPROGRAMMING TECHNIQUE; CELL THERAPY; EMBRYONIC STEM CELL; EMBRYONIC STEM CELL THERAPY; ENDOTHELIAL PROGENITOR CELL; EXOSOME; EXTRACELLULAR VESICLE DERIVED STEM CELL; GENETIC TRANSDUCTION; HUMAN; INDUCED PLURIPOTENT STEM CELL; INDUCED PLURIPOTENT STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELL; MYOCARDIAL DISEASE; MYOCARDIAL REGENERATION THERAPY; NONHUMAN; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION; UMBILICAL CORD BLOOD DERIVED MESENCHYMAL STEM CELL; XENOGENEIC STEM CELL THERAPY;

EID: 84994453140     PISSN: None     EISSN: 16879678     Source Type: Journal    
DOI: 10.1155/2016/4285938     Document Type: Review

References (110)

1. T. H. Chao, I. C. Chen, S. Y. Tseng, and Y. H. Li, "Pluripotent stem cell therapy in ischemic cardiovascular disease," Zhonghua Minguo Xin Zang Xue Hui Za Zhi, vol. 30, no. 5, pp. 365-374, 2014.
2. P. Elliott, B. Andersson, E. Arbustini et al., "Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases," European Heart Journal, vol. 29, no. 2, pp. 270-276, 2008.
3. I. Y. Chen, E. Matsa, and J. C. Wu, "Induced pluripotent stem cells: at the heart of cardiovascular precision medicine," Nature Reviews Cardiology, vol. 13, no. 6, pp. 333-349, 2016.
4. M. Gnecchi, Z. Zhang, A. Ni, and V. J. Dzau, "Paracrine mechanisms in adult stem cell signaling and therapy," Circulation Research, vol. 103, no. 11, pp. 1204-1219, 2008.
5. Y. L. Tang, Q. Zhao, X. Qin et al., "Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in ratmodel of myocardial infarction," The Annals of Thoracic Surgery, vol. 80, no. 1, pp. 229-237, 2005.
6. R. H. Lee, A. A. Pulin, M. J. Seo et al., "Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6," Cell Stem Cell, vol. 5, no. 1, pp. 54-63, 2009.
7. J. Y. Oh, M. K. Kim, M. S. Shin et al., "The anti-inflammatory and anti-angiogenic role of mesenchymal stem cells in corneal wound healing following chemical injury," STEM CELLS, vol. 26, no. 4, pp. 1047-1055, 2008.
8. A. Uccelli, L. Moretta, and V. Pistoia, "Mesenchymal stem cells in health and disease," Nature Reviews Immunology, vol. 8, no. 9, pp. 726-736, 2008.
9. H. J. Hwang, W. Chang, B.-W. Song et al., "Antiarrhythmic potential of mesenchymal stem cell is modulated by hypoxic environment," Journal of the American College of Cardiology, vol. 60, no. 17, pp. 1698-1706, 2012.
10. Y.-J. Geng, "Molecular mechanisms for cardiovascular stem cell apoptosis and growth in the hearts with atherosclerotic coronary disease and ischemic heart failure," Annals of the New York Academy of Sciences, vol. 1010, pp. 687-697, 2003.
11. W. Chang, C. Y. Lee, J.-H. Park et al., "Survival of hypoxic human mesenchymal stem cells is enhanced by a positive feedback loop involving mir-210 and hypoxia-inducible factor 1," Journal of Veterinary Science, vol. 14, no. 1, pp. 69-76, 2013.
12. R. Damoiseaux, S. P. Sherman, J. A. Alva, C. Peterson, and A. D. Pyle, "Integrated chemical genomics reveals modifiers of survival in human embryonic stem cells," STEM CELLS, vol. 27, no. 3, pp. 533-542, 2009.
13. W. Chang, R. Kim, S. I. Park et al., "Enhanced healing of rat calvarial bone defects with hypoxic conditioned medium from mesenchymal stem cells through increased endogenous stem cell migration via regulation of ICAM-1 targeted-microRNA-221," Molecules and Cells, vol. 38, no. 7, pp. 643-650, 2015.
14. Y. Zhao, E. Samal, and D. Srivastava, "Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis," Nature, vol. 436, no. 7048, pp. 214-220, 2005.
15. J.-F. Chen, E. M. Mandel, J. M. Thomson et al., "The role of microRNA-1 and microRNA-133 in skeletalmuscle proliferation and differentiation," Nature Genetics, vol. 38, no. 2, pp. 228-233, 2006.
16. H. Sadek, B. Hannack, E. Choe et al., "Cardiogenic small molecules that enhance myocardial repair by stem cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 16, pp. 6063-6068, 2008.
17. O. Caspi, I. Huber, I. Kehat et al., "Transplantation of human embryonic stem cell-derived cardiomyocytes improvesmyocardial performance in infarcted rat hearts," Journal of the American College of Cardiology, vol. 50, no. 19, pp. 1884-1893, 2007.
18. Z. Li, K. D. Wilson, B. Smith et al., "Functional and transcriptional characterization of human embryonic stem cell-derived endothelial cells for treatment of myocardial infarction," PLoS ONE, vol. 4, no. 12, Article IDe8443, 2009.
19. R141W transgenic mouse of dilated cardiomyopathy," European Journal of Cell Biology, vol. 95, no. 1, pp. 57-67, 2016.
20. C. Toma, M. F. Pittenger, K. S. Cahill, B. J. Byrne, and P. D. Kessler, "Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart," Circulation, vol. 105, no. 1, pp. 93-98, 2002.
21. S. V. Rojas, A. Martens, R. Zweigerdt et al., "Transplantation effectiveness of induced pluripotent stem cells is improved by a fibrinogen biomatrix in an experimental model of ischemic heart failure," Tissue Engineering Part A, vol. 21, no. 13-14, pp. 1991-2000, 2015.
22. P. M. M. Ja, Q. Miao, N. G. Zhen Tee et al., "iPSC-derived human cardiac progenitor cells improve ventricular remodelling via angiogenesis and interstitial networking of infarcted myocardium," Journal of Cellular and Molecular Medicine, vol. 20, no. 2, pp. 323-332, 2016.
23. A. Kawamoto, H.-C. Gwon, H. Iwaguro et al., "Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia," Circulation, vol. 103, no. 5, pp. 634-637, 2001.
24. F. Song, F. Hua, H. Li et al., "Cardiac stem cell transplantation with 2,3,5,4′-tetrahydroxystilbehe-2-O-β-D-glucoside improves cardiac function in rat myocardial infarction model," Life Sciences, vol. 158, pp. 37-45, 2016.
25. M. J. Sarnak, A. S. Levey, A. C. Schoolwerth et al., "Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention," Hypertension, vol. 42, no. 5, pp. 1050-1065, 2003.
26. M. Lafeber, W. Spiering, F. L. Visseren, and D. E. Grobbee, "Multifactorial prevention of cardiovascular disease in patients with hypertension: the cardiovascular polypill," Current Hypertension Reports, vol. 18, no. 5, article 40, 2016.
27. R. M. Conroy, K. Pyörälä, A. P. Fitzgerald et al., "Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project," European Heart Journal, vol. 24, no. 11, pp. 987-1003, 2003.
28. J. Perk, G. De Backer, H. Gohlke et al., "European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)," European Heart Journal, vol. 33, no. 13, pp. 1635-1701, 2012.
29. A. R. Rahimi, J. A. Spertus, K. J. Reid, S. M. Bernheim, and H. M. Krumholz, "Financial barriers to health care and outcomes after acute myocardial infarction," The Journal of the American Medical Association, vol. 297, no. 10, pp. 1063-1072, 2007.
30. F. Mookadam and H. M. Arthur, "Social support and its relationship to morbidity and mortality after acute myocardial infarction: systematic overview," Archives of Internal Medicine, vol. 164, no. 14, pp. 1514-1518, 2004.
31. E. D. Eaker, L. M. Sullivan, M. Kelly-Hayes, R. B. D'Agostino Sr., and E. J. Benjamin, "Marital status, marital strain, and risk of coronary heart disease or total mortality: the Framingham Offspring Study," Psychosomatic Medicine, vol. 69, no. 6, pp. 509-513, 2007.
32. R. Rugulies, "Depression as a predictor for coronary heart disease. A review and meta-analysis," American Journal of Preventive Medicine, vol. 23, no. 1, pp. 51-61, 2002.
33. J. W. Smoller, M. H. Pollack, S. Wassertheil-Smoller et al., "Panic attacks and risk of incident cardiovascular events among postmenopausal women in the Women's Health Initiative Observational Study," Archives of General Psychiatry, vol. 64, no. 10, pp. 1153-1160, 2007.
34. Y. Chida and A. Steptoe, "The association of anger and hostility with future coronary heart disease. a meta-analytic review of prospective evidence," Journal of the American College of Cardiology, vol. 53, no. 11, pp. 936-946, 2009.
35. M. Liu, X. Li, R. Sun, Y. Zeng, S. Chen, and P. Zhang, "Vitamin D nutritional status and the risk for cardiovascular disease (review)," Experimental and Therapeutic Medicine, vol. 11, no. 4, pp. 1189-1193, 2016.
36. P. Andersson, E. Rydberg, and R. Willenheimer, "Primary hyperparathyroidism and heart disease-a review," European Heart Journal, vol. 25, no. 20, pp. 1776-1787, 2004.
37. W. Xiang, J. Kong, S. Chen et al., "Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems," American Journal of Physiology-Endocrinology and Metabolism, vol. 288, no. 1, pp. E125-E132, 2005.
38. T. D. O'Connell, J. E. Berry, A. K. Jarvis, M. J. Somerman, and R. U. Simpson, "1, 25-Dihydroxyvitamin D3 regulation of cardiac myocyte proliferation and hypertrophy," American Journal of Physiology, vol. 272, no. 4, part 2, pp. H1759-H1769, 1997.
39. S. Bae, S. S. Singh, H. Yu, J. Y. Lee, B. R. Cho, and P. M. Kang, "Vitamin D signaling pathway plays an important role in the development of heart failure aftermyocardial infarction," Journal of Applied Physiology, vol. 114, no. 8, pp. 979-987, 2013.
40. E. G. Nabel, "Cardiovascular disease," The New England Journal of Medicine, vol. 349, no. 1, pp. 60-72, 2003.
41. Q. Sun, Z. Zhang, and Z. Sun, "The potential and challenges of using stem cells for cardiovascular repair and regeneration," Genes and Diseases, vol. 1, no. 1, pp. 113-119, 2014.
42. M. L. Moreira, P. da Costa Medeiros, S. A. de Souza, B. Gutfilen, and P. H. Rosado-de-Castro, " In vivo tracking of cell therapies for cardiac diseases with nuclear medicine," Stem Cells International, vol. 2016, Article ID 3140120, 15 pages, 2016.
43. H. S. Bernstein and D. Srivastava, "Stem cell therapy for cardiac disease," Pediatric Research, vol. 71, no. 4, part 2, pp. 491-499, 2012.
44. R. K. Sharma, D. J. Voelker, R. Sharma, and H. K. Reddy, "Understanding the application of stem cell therapy in cardiovascular diseases," Stem Cells and Cloning: Advances and Applications, vol. 5, no. 1, pp. 29-37, 2012.
45. M. Yousefi, V. Hajihoseini, W. Jung et al., "Embryonic stem cell interactomics: the beginning of a long road to biological function," Stem Cell Reviews and Reports, vol. 8, no. 4, pp. 1138-1154, 2012.
46. D. C. Kraushaar and K. Zhao, "The epigenomics of embryonic stem cell differentiation," International Journal of Biological Sciences, vol. 9, no. 10, pp. 1134-1144, 2013.
47. S. G. Nir, R. David, M. Zaruba, W.-M. Franz, and J. Itskovitz-Eldor, "Human embryonic stem cells for cardiovascular repair," Cardiovascular Research, vol. 58, no. 2, pp. 313-323, 2003.
48. 2+ channel blockers," Differentiation, vol. 48, no. 3, pp. 173-182, 1991.
49. S. S. Wong and H. S. Bernstein, "Cardiac regeneration using human embryonic stem cells: producing cells for future therapy," Regenerative Medicine, vol. 5, no. 5, pp. 763-775, 2010.
50. Q. Xiong, L. Ye, P. Zhang et al., "Bioenergetic and functional consequences of cellular therapy: activation of endogenous cardiovascular progenitor cells," Circulation Research, vol. 111, no. 4, pp. 455-468, 2012.
51. C. Freund and C. L. Mummery, "Prospects for pluripotent stem cell-derived cardiomyocytes in cardiac cell therapy and as disease models," Journal of Cellular Biochemistry, vol. 107, no. 4, pp. 592-599, 2009.
52. H. Ebelt, M. Jungblut, Y. Zhang et al., "Cellular cardiomyoplasty: improvement of left ventricular function correlates with the release of cardioactive cytokines," Stem Cells, vol. 25, no. 1, pp. 236-244, 2007.
53. K. N. Ivey, A. Muth, J. Arnold et al., "MicroRNA regulation of cell lineages in mouse and human embryonic stem cells," Cell Stem Cell, vol. 2, no. 3, pp. 219-229, 2008.
54. D. Weber, J. Heisig, S. Kneitz, E. Wolf, M. Eilers, and M. Gessler, "Mechanisms of epigenetic and cell-type specific regulation of Hey target genes in ES cells and cardiomyocytes," Journal of Molecular and Cellular Cardiology, vol. 79, pp. 79-88, 2015.
55. E. C. Perin, Y.-J. Geng, and J. T. Willerson, "Adult stem cell therapy in perspective," Circulation, vol. 107, no. 7, pp. 935-938, 2003.
56. M. Murata, S. Tohyama, and K. Fukuda, "Impacts of recent advances in cardiovascular regenerative medicine on clinical therapies and drug discovery," Pharmacology and Therapeutics, vol. 126, no. 2, pp. 109-118, 2010.
57. E. Fuchs and J. A. Segre, "Stem cells: a new lease on life," Cell, vol. 100, no. 1, pp. 143-155, 2000.
58. R. Poulsom, M. R. Alison, S. J. Forbes, and N. A. Wright, "Adult stem cell plasticity," The Journal of Pathology, vol. 197, no. 4, pp. 441-456, 2002.
59. P. Bianco, M. Riminucci, S. Gronthos, and P. G. Robey, "Bone marrow stromal stem cells: nature, biology, and potential applications," STEM CELLS, vol. 19, no. 3, pp. 180-192, 2001.
60. S. Ohnishi, H. Sumiyoshi, S. Kitamura, and N. Nagaya, "Mesenchymal stem cells attenuate cardiac fibroblast proliferation and collagen synthesis through paracrine actions," FEBS Letters, vol. 581, no. 21, pp. 3961-3966, 2007.
61. B. Cai, X. Tan, Y. Zhang et al., "Mesenchymal stem cells and cardiomyocytes interplay to prevent myocardial hypertrophy," Stem Cells Translational Medicine, vol. 4, no. 12, pp. 1425-1435, 2015.
62. R. S. Ripa, M. Haack-Sørensen, Y. Wang et al., "Bone marrow derived mesenchymal cell mobilization by granulocyte-colony stimulating factor after acute myocardial infarction: results from the Stem Cells in Myocardial Infarction (STEMMI) trial," Circulation, vol. 116, no. 11, supplement, pp. I24-I30, 2007.
63. V. Volarevic, N. Arsenijevic, M. L. Lukic, and M. Stojkovic, "Concise review: mesenchymal stem cell treatment of the complications of diabetes mellitus," Stem Cells, vol. 29, no. 1, pp. 5-10, 2011.
64. J.-Y. Hahn, H.-J. Cho, H.-J. Kang et al., "Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction," Journal of the American College of Cardiology, vol. 51, no. 9, pp. 933-943, 2008.
65. C. Siciliano, I. Chimenti, M. Ibrahim et al., "Cardiosphere conditioned media influence the plasticity of human mediastinal adipose tissue-derived mesenchymal stem cells," Cell Transplantation, vol. 24, no. 11, pp. 2307-2322, 2015.
66. D. A. De Ugarte, Z. Alfonso, P. A. Zuk et al., "Differential expression of stem cell mobilization-associated molecules on multi-lineage cells from adipose tissue and bone marrow," Immunology Letters, vol. 89, no. 2-3, pp. 267-270, 2003.
67. A. Schäffler and C. Büchler, "Concise review: adipose tissuederived stromal cells-basic and clinical implications for novel cell-based therapies," Stem Cells, vol. 25, no. 4, pp. 818-827, 2007.
68. L. Casteilla, V. Planat-Bénard, B. Cousin, P. Laharrague, and P. Bourin, "Vascular and endothelial regeneration," Current Stem Cell Research and Therapy, vol. 5, no. 2, pp. 141-144, 2010.
69. I. Perea-Gil, M. Monguió-Tortajada, C. Gálvez-Montón, A. Bayes-Genis, F. E. Borràs, and S. Roura, "Preclinical evaluation of the immunomodulatory properties of cardiac adipose tissue progenitor cells using umbilical cord blood mesenchymal stem cells: a direct comparative study," Bio Med Research International, vol. 2015, Article ID 439808, 9 pages, 2015.
70. M. Lee, S. Y. Jeong, J. Ha et al., "Low immunogenicity of allogeneic human umbilical cord blood-derived mesenchymal stem cells in vitro and in vivo," Biochemical and Biophysical Research Communications, vol. 446, no. 4, pp. 983-989, 2014.
71. G. Yannarelli, V. Dayan, N. Pacienza, C.-J. Lee, J. Medin, and A. Keating, "Human umbilical cord perivascular cells exhibit enhanced cardiomyocyte reprogramming and cardiac function after experimental acute myocardial infarction," Cell Transplantation, vol. 22, no. 9, pp. 1651-1666, 2013.
72. A. P. Beltrami, L. Barlucchi, D. Torella et al., "Adult cardiac stem cells are multipotent and support myocardial regeneration," Cell, vol. 114, no. 6, pp. 763-776, 2003.
73. P. Oettgen, A. J. Boyle, S. P. Schulman, and J. M. Hare, "Cardiac stem cell therapy. Need for optimization of efficacy and safety monitoring," Circulation, vol. 114, no. 4, pp. 353-358, 2006.
74. T. Asahara, T. Murohara, A. Sullivan et al., "Isolation of putative progenitor endothelial cells for angiogenesis," Science, vol. 275, no. 5302, pp. 964-967, 1997.
75. E. Oikonomou, G. Siasos, M. Zaromitidou et al., "Atorvastatin treatment improves endothelial function through endothelial progenitor cellsmobilization in ischemic heart failure patients," Atherosclerosis, vol. 238, no. 2, pp. 159-164, 2015.
76. K. Takahashi and S. Yamanaka, "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors," Cell, vol. 126, no. 4, pp. 663-676, 2006.
77. F. González, S. Boué, and J. C. Izpisua Belmonte, "Methods for making induced pluripotent stem cells: Reprogramming à la carte," Nature Reviews Genetics, vol. 12, no. 4, pp. 231-242, 2011.
78. M. Csobonyeiova, S. Polak, and L. Danisovic, "Perspectives of induced pluripotent stem cells for cardiovascular system regeneration," Experimental Biology and Medicine, vol. 240, no. 5, pp. 549-556, 2015.
79. K. Narsinh, K. H. Narsinh, and J. C. Wu, "Derivation of human induced pluripotent stem cells for cardiovascular disease modeling," Circulation Research, vol. 108, no. 9, pp. 1146-1156, 2011.
80. K. Schenke-Layland, K. E. Rhodes, E. Angelis et al., "Reprogrammed mouse fibroblasts differentiate into cells of the cardiovascular and hematopoietic lineages," Stem Cells, vol. 26, no. 6, pp. 1537-1546, 2008.
81. Z. Tong, A. Solanki, A. Hamilos et al., "Application of biomaterials to advance induced pluripotent stem cell research and therapy," The EMBO Journal, vol. 34, no. 8, pp. 987-1008, 2015.
82. F. Jia, K. D. Wilson, N. Sun et al., "A nonviral minicircle vector for deriving human iPS cells," Nature Methods, vol. 7, no. 3, pp. 197-199, 2010.
83. M. Ieda, J.-D. Fu, P. Delgado-Olguin et al., "Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors," Cell, vol. 142, no. 3, pp. 375-386, 2010.
84. J. X. Chen, M. Krane, M.-A. Deutsch et al., "Inefficient reprogramming of fibroblasts into cardiomyocytes using Gata4, Mef2c, and Tbx5," Circulation Research, vol. 111, no. 1, pp. 50-55, 2012.
85. K. Song, Y.-J. Nam, X. Luo et al., "Heart repair by reprogramming non-myocytes with cardiac transcription factors," Nature, vol. 485, no. 7400, pp. 599-604, 2012.
86. T. M. Jayawardena, B. Egemnazarov, E. A. Finch et al., "MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes," Circulation Research, vol. 110, no. 11, pp. 1465-1473, 2012.
87. P. W. Burridge, E. Matsa, P. Shukla et al., "Chemically defined generation of human cardiomyocytes," Nature Methods, vol. 11, no. 8, pp. 855-860, 2014.
88. P. Hou, Y. Li, X. Zhang et al., "Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds," Science, vol. 341, no. 6146, pp. 651-654, 2013.
89. X. Lu and T. Zhao, "Clinical therapy using iPSCs: hopes and challenges," Genomics, Proteomics & Bioinformatics, vol. 11, no. 5, pp. 294-298, 2013.
90. H. Masumoto, T. Ikuno, M. Takeda et al., "Human iPS cellengineered cardiac tissue sheets with cardiomyocytes and vascular cells for cardiac regeneration," Scientific Reports, vol. 4, article 6716, 2014.
91. M. Tong, Z. Lv, L. Liu et al., "Mice generated from tetraploid complementation competent iPS cells show similar developmental features as those from ES cells but are prone to tumorigenesis," Cell Research, vol. 21, no. 11, pp. 1634-1637, 2011.
92. K. Okita, T. Ichisaka, and S. Yamanaka, "Generation of germline-competent induced pluripotent stem cells," Nature, vol. 448, no. 7151, pp. 313-317, 2007.
93. T. Zhao, Z.-N. Zhang, Z. Rong, and Y. Xu, "Immunogenicity of induced pluripotent stem cells," Nature, vol. 474, no. 7350, pp. 212-216, 2011.
94. C. E. Pasi, A. Dereli-Öz, S. Negrini et al., "Genomic instability in induced stemcells," Cell Death and Differentiation, vol. 18, no. 5, pp. 745-753, 2011.
95. S. Funakoshi, K. Miki, T. Takaki et al., "Enhanced engraftment, proliferation, and therapeutic potential in heart using optimized human iPSC-derived cardiomyocytes," Scientific Reports, vol. 6, Article ID 19111, 2016.
96. S. El Andaloussi, I. Mäger, X. O. Breakefield, and M. J. A. Wood, "Extracellular vesicles: biology and emerging therapeutic opportunities," Nature Reviews Drug Discovery, vol. 12, no. 5, pp. 347-357, 2013.
97. M. Simons and G. Raposo, "Exosomes-vesicular carriers for intercellular communication," Current Opinion in Cell Biology, vol. 21, no. 4, pp. 575-581, 2009.
98. S. Mathivanan and R. J. Simpson, "Exo Carta: a compendium of exosomal proteins and RNA," Proteomics, vol. 9, no. 21, pp. 4997-5000, 2009.
99. M. Mittelbrunn, C. Gutiérrez-Vázquez, C. Villarroya-Beltri et al., "Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells," Nature Communications, vol. 2, no. 1, article 282, 2011.
100. R. C. Lai, F. Arslan, M. M. Lee et al., "Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury," Stem Cell Research, vol. 4, no. 3, pp. 214-222, 2010.
101. C. Lee, S. A. Mitsialis, M. Aslam et al., "Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxiainduced pulmonary hypertension," Circulation, vol. 126, no. 22, pp. 2601-2611, 2012.
102. M. Khan, E. Nickoloff, T. Abramova et al., "Embryonic stem cell-derived exosomes promote endogenous repairmechanisms and enhance cardiac function followingmyocardial infarction," Circulation Research, vol. 117, no. 1, pp. 52-64, 2015.
103. L. Barile, V. Lionetti, E. Cervio et al., "Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction," Cardiovascular Research, vol. 103, no. 4, pp. 530-541, 2014.
104. K. R. Vrijsen, J. P. G. Sluijter, M. W. L. Schuchardt et al., "Cardiomyocyte progenitor cell-derived exosomes stimulate migration of endothelial cells," Journal of Cellular and Molecular Medicine, vol. 14, no. 5, pp. 1064-1070, 2010.
105. L. Chen, Y. Wang, Y. Pan et al., "Cardiac progenitor-derived exosomes protect ischemic myocardium from acute ischemia/reperfusion injury," Biochemical and Biophysical Research Communications, vol. 431, no. 3, pp. 566-571, 2013.
106. R. C. Lai, T. S. Chen, and S. K. Lim, "Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease," Regenerative Medicine, vol. 6, no. 4, pp. 481-492, 2011.
107. P. Yde, B. Mengel, M. H. Jensen, S. Krishna, and A. Trusina, "Modeling the NF-κB mediated inflammatory response predicts cytokine waves in tissue," BMC Systems Biology, vol. 5, article 115, 2011.
108. A. Khosravi, C. M. Cutler, M. H. Kelly et al., "Determination of the elimination half-life of fibroblast growth factor-23," The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 6, pp. 2374-2377, 2007.
109. Y. Takahashi, M. Nishikawa, H. Shinotsuka et al., "Visualization and in vivo tracking of the exosomes of murine melanoma B16-BL6 cells in mice after intravenous injection," Journal of Biotechnology, vol. 165, no. 2, pp. 77-84, 2013.
110. L. Biancone, S. Bruno, M. C. Deregibus, C. Tetta, and G. Camussi, "Therapeutic potential of mesenchymal stem cellderived microvesicles," Nephrology Dialysis Transplantation, vol. 27, no. 8, pp. 3037-3042, 2012.